Anika Therapeutics (NASDAQ: ANIK) and Cardiome Pharma Corporation (NASDAQ:CRME) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Anika Therapeutics and Cardiome Pharma Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics 30.44% 14.88% 13.78%
Cardiome Pharma Corporation -110.95% -78.51% -38.30%

Earnings and Valuation

This table compares Anika Therapeutics and Cardiome Pharma Corporation’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Anika Therapeutics $111.36 million 7.89 $56.02 million $2.26 26.52
Cardiome Pharma Corporation $23.21 million 2.93 -$17.41 million ($0.83) -2.42

Anika Therapeutics has higher revenue and earnings than Cardiome Pharma Corporation. Cardiome Pharma Corporation is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Anika Therapeutics and Cardiome Pharma Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics 0 0 0 0 N/A
Cardiome Pharma Corporation 0 0 4 0 3.00

Cardiome Pharma Corporation has a consensus price target of $7.58, indicating a potential upside of 277.28%. Given Cardiome Pharma Corporation’s higher possible upside, analysts clearly believe Cardiome Pharma Corporation is more favorable than Anika Therapeutics.

Risk and Volatility

Anika Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Cardiome Pharma Corporation has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Insider & Institutional Ownership

84.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 55.2% of Cardiome Pharma Corporation shares are owned by institutional investors. 6.6% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Anika Therapeutics beats Cardiome Pharma Corporation on 10 of the 12 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

About Cardiome Pharma Corporation

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Receive News & Stock Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related stocks with our FREE daily email newsletter.